Get the Stockscreener App
0.6196
2.70%
0.0163
After Hours:
.62
0.0004
+0.06%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Vaxart Inc stock is traded at $0.6196, with a volume of 1.56M.
It is up +2.70% in the last 24 hours and up +1.94% over the past month.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.
See More
Previous Close:
$0.6033
Open:
$0.6
24h Volume:
1.56M
Relative Volume:
1.20
Market Cap:
$140.95M
Revenue:
$9.10M
Net Income/Loss:
$-82.47M
P/E Ratio:
-0.8153
EPS:
-0.76
Net Cash Flow:
$-72.32M
1W Performance:
+4.66%
1M Performance:
+1.94%
6M Performance:
-13.81%
1Y Performance:
+2.75%
1-Day Range:
$0.59
$0.6399
1-Week Range:
$0.5347
$0.6399
52-Week Range:
$0.52
$1.54
Vaxart Inc Stock (VXRT) Company Profile
Name
Vaxart Inc
Sector
Industry
Phone
(650) 550-3500
Address
170 HARBOR WAY, SUITE 300, SOUTH SAN FRANCISCO, CA
Compare VXRT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VXRT
Vaxart Inc
|
0.6196 | 140.95M | 9.10M | -82.47M | -72.32M | -0.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Vaxart Inc Stock (VXRT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-15-24 | Initiated | Oppenheimer | Outperform |
| Dec-29-21 | Resumed | Jefferies | Buy |
| Nov-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-29-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jun-24-21 | Initiated | Jefferies | Buy |
| Jun-11-21 | Initiated | Piper Sandler | Overweight |
| Aug-12-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
View All
Vaxart Inc Stock (VXRT) Latest News
Vaxart (NASDAQ:VXRT) Share Price Passes Below 200-Day Moving AverageWhat's Next? - MarketBeat
Vaxart Investors Win Class Cert. Over COVID Shot On 2nd Try - Law360
Vaxart Investors Get Class Status on Second Try Against Insider - Bloomberg Law
Contrasting Tenaya Therapeutics (NASDAQ:TNYA) and Vaxart (NASDAQ:VXRT) - Defense World
No time to wait on development of second-generation vaccines - The Hill
Vaxart (NASDAQ:VXRT) Share Price Crosses Below 200 Day Moving AverageTime to Sell? - MarketBeat
Akin Gump 'Totally Messed Up' With Texts, Vaxart Judge Says - Law360
Vaxart Hits Key Milestone in Phase 2b Oral COVID Vaccine Trial, Backed by $456M BARDA Deal - StockTitan
Vaxart, Inc. (NASDAQ:VXRT) Shares Sold by Sio Capital Management LLC - MarketBeat
Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside - AOL
VXRT (Vaxart) Enterprise Value : $95.98 Mil (As of Nov. 23, 2024) - GuruFocus.com
B. Riley Has Optimistic Outlook of Vaxart FY2024 Earnings - MarketBeat
COVID-19 vaccine company Vaxart under US federal investigation - Telegrafi
What is B. Riley's Estimate for Vaxart FY2027 Earnings? - MarketBeat
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Vaxart Grants 91.5K Equity Awards to New Employees Under Inducement Plan | VXRT Stock News - StockTitan
Investors Give Vaxart, Inc. (NASDAQ:VXRT) Shares A 29% Hiding - Simply Wall St
Vaxart Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Vaxart, Inc. Reports Third Quarter 2024 Financial Results – - Defense World
Vaxart, Inc. (NASDAQ:VXRT) Q3 2024 Earnings Call Transcript - Insider Monkey
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Earnings call: Vaxart reports progress in vaccine programs and financial growth - Investing.com
Vaxart Inc (NASDAQ: VXRT): Blank Check On Growth? - Stocks Register
VAXART, INC. (VXRT) Reports Q3 Loss, Tops Revenue Estimates - MSN
Vaxart Provides Business Update and Reports Third Quarter 2024 Financial Results - The Manila Times
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and Financial Growth - GuruFocus.com
Vaxart Inc (VXRT) Q3 2024 Earnings Call Highlights: Advancements in Oral Vaccine Platform and ... - Yahoo Finance
Vaxart Inc reports results for the quarter ended September 30Earnings Summary - XM
Vaxart’s Q3 2024: Progress in Oral Vaccine Development - TipRanks
Vaxart's Q3 Revenue Jumps 133% to $4.9M, Narrows Losses Amid COVID Trial Progress | VXRT Stock News - StockTitan
Vaxart (VXRT) Scheduled to Post Earnings on Wednesday - MarketBeat
Vaxart to Host Third Quarter 2024 Business Update and Financial Results Conference Call on November 13 - The Manila Times
Vaxart (VXRT) Sets Q3 2024 Earnings Call for November 13: Key Updates Coming | VXRT Stock News - StockTitan
While shareholders of Vaxart (NASDAQ:VXRT) are in the black over 5 years, those who bought a week ago aren't so fortunate - Simply Wall St
Vaxart (NASDAQ:VXRT) Stock Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Investing in Vaxart (NASDAQ:VXRT) five years ago would have delivered you a 127% gain - Yahoo Finance
VXRTVaxart, Inc Latest Stock News & Market Updates - StockTitan
Vaxart (NASDAQ:VXRT) Shares Cross Below 200 Day Moving AverageShould You Sell? - MarketBeat
Vaxart to Showcase its COVID-19 and Norovirus Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2024 - StockTitan
Millennium Management LLC Has $2.66 Million Stock Holdings in Vaxart, Inc. (NASDAQ:VXRT) - MarketBeat
Check out these key findings about Vaxart Inc (VXRT) - SETE News
Vaxart to Present Norovirus Data at IDWeek 2024 Underscoring Commitment to Address Significant Unmet Need - StockTitan
VXRT stock rated an Outperform by Oppenheimer - Knox Daily
Did Vaxart Inc (VXRT) perform well in the last session? - US Post News
Best Penny Stocks Under $1 To Buy Now - AOL
Vaxart Inc (VXRT) Q2 2024 Earnings Call Highlights: Revenue Surge and Strategic Advances - Yahoo Finance
Vaxart ends agreement with sales agents, halts stock sales By Investing.com - Investing.com Australia
Vaxart, Inc. Terminates Controlled Equity Offering Sales Agreement with Sales Agents - MarketBeat
Vaxart ends agreement with sales agents, halts stock sales - Investing.com India
Vaxart Ends Sales Agreement, Halts Stock Offering - TipRanks
Vaxart Inc Stock (VXRT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):